contact pfizer CDC has Web(COVID-19 Vaccine, mRNA) COPPER (cupric chloride) CORLOPAM (fenoldopam mesylate) CORTEF (hydrocortisone tablets) CORTISPORIN (neomycin and polymyxin B sulfates, and hydrocortisone acetate) CORVERT (ibutilide fumarate injection) CORZIDE (nadolol and bendroflumethiazide) COVERA-HS (verapamil hydrochloride extended Recognized towards immunity in US. Document the current date, the vaccine lot number, and the updated expiration date in the appropriate columns, including the information source and the name of the person completing this form. Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website. SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, 50 mcg/0.5 mL dose, COVID-19, mRNA, LNP-S, PF, 50 mcg/0.5 mL dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use, EUA-authorized for ages 6 months to < 6 years, 25 mcg/0.25 mL dose For pediatric primary series and IC doses for ages 6 mo to <6 years, SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, preservative free, pediatric 25 mcg/0.25 mL dose, COVID-19, mRNA, LNP-S, PF, pediatric 25 mcg/0.25 mL dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use, Moderna COVID-19 Vaccine Bivalent Booster, 0.5 mL adult dose Original and Omicron BA.4 & BA.5 COVID-19 strains, SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent booster, preservative free, 50 mcg/0.5 mL or 25mcg/0.25mL dose, COVID-19, mRNA, LNP-S, bivalent booster, PF, 50 mcg/0.5 mL or 25mcg/0.25mL dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use, EUA-authorized for ages 6 yrs to < 12 yrs, 0.25 mL dose for 6-11 yrs of Original and Omicron BA.4 & BA.5 COVID-19 strains, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use, Moderna COVID-19 Vaccine Bivalent Booster for ages 6 months to < 6 yrs, 10 mcg/0.2 mL dose booster of Original and Omicron BA.4 & BA.5 COVID-19 strains, SARS-COV-2 (COVID-19) vaccine, mRNA, spike protein, LNP, bivalent booster, preservative free, 10 mcg/0.2 mL dose, COVID-19, mRNA, LNP-S, bivalent booster, PF, 10 mcg/0.2 mL, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, for intramuscular use. If a vaccine is not authorized, the code will be retired. Webpfizer customer service. Disclaimer The packaging for Pfizer- The Lot Number of the left side of the monovalent vaccine label are outlined in green. WebHow will the Pfizer-BioNTech COVID-19 vaccine be distributed? On 8/31/2022, EUA rescinded adult booster dose from this vial. Ahntastic Adventures in Silicon Valley Selection required to narrow down to correct Administrative Code. Emergency uses of the vaccines have not been approved or licensed by the U.S. Food and Drug Administration (FDA), but have been authorized by the FDA, under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) in individuals aged 6 months and older. 6. Webwho wins student body president riverdale. >l$GO}Un}};]3kvpM[Ogw},O/ge_ua?&mwvGn/WyI}&^ccV.v[:Y~,pb~?+ Tracking COVID-19 vaccine distribution and administration activities requires collaboration between public and private information technology (IT) systems and integration of existing and newly developed IT systems. iPhone or These cookies perform functions like remembering presentation options or choices and, in some cases, delivery of web content that based on self-identified area of interests. pfizer lot number lookup expiration date. Which dose is being administered? 2) The lot number and expiration date. Copyright 1995 - 2023 American Medical Association. Contact [email protected] to advise FDA of your intent to begin submitting LDD Reports electronically. The emergency uses are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner. Registered users can now access COVID-19 These cookies may also be used for advertising purposes by these third parties. Moderna has provided the following statement regarding the SPIKEVAX branded NDCs and labels: EUA-authorized for ages 6 years to < 12 years, 50 mcg/0.50 mL pediatric primary series for ages 6 yrs to <12 years, Moderna Statement: These codes have been provided in anticipation of FDA authorization and need. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, for intramuscular use, 100 mcg/0.5 mL for adult 18+ (Same formulation and concentration as EUA product). The second field is the edition date of the VIS. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website. Step 1. If the test is not successful, review Step 2. All information these cookies collect is aggregated and therefore anonymous. All information these cookies collect is aggregated and therefore anonymous. You will be subject to the destination website's privacy policy when you follow the link. For further information/assistance contact [email protected]. Vaccine Information Statement (VIS) Lookup Table. Pfizer COVID-19 Vaccine: 5 through 11 years formulation (orange cap) Formulation does NOT have expiration printed on vial Instead, each vial has the lot number and date of manufacture printed on the label 91303 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike All codes will be retired, Sanofi Pasteur COVID-19 Vaccine, booster dose, adult, 5mcg/0.5mL dose, including added AS03 adjuvant, booster dose only, SARS-COV-2 (COVID-19) vaccine, D614, prefusion spike recombinant protein subunit (CoV2 preS dTM), AS03 adjuvant added, preservative free, 5mcg/0.5mL dose, COVID-19, D614, recomb, preS dTM, AS03 adjuvant add, PF, 5mcg/0.5mL, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, monovalent, preservative free, 5 mcg/0.5 mL dosage, adjuvant AS03 emulsion, for intramuscular use, SARS-COV-2 (COVID-19) vaccine, UNSPECIFIED. WebIn this Report, registered users can access COVID-19 vaccine lot numbers, expiration dates, and National Drug Codes (NDCs) provided by the vaccine manufacturers to CDC This procedure is intended to assist manufacturers of vaccines and other biological products to electronically submit post marketing lot distribution data to FDA under 21 CFR 600.81. Centers for Disease Control and Prevention. The FDA issued its initial Emergency Use Authorization for the Novavax COVID-19 vaccine on Wednesday July 13, 2022. To receive email updates about this page, enter your email address: We take your privacy seriously. Questions regarding this table should be directed to the IIS Technical Assistance Team (or use IIS mailing address). J&J/Janssen Moderna Pfizer Lot Number Expiration Date Lot Number Expiration Date Lot Number To support this effort, the CDC is working closely with data partners responsible for the creation and distribution of vaccine codes and drug compendia publishers to coordinate the release of codes in advance of potential EUAs to enable systems and users that require these codes to prepare in advance. The following SPIKEVAX products are not anticipated to be manufactured and orderable. New concentration, 50 mcg/0.50 mL for booster dose adults 18+ yrs, also authorized for primary series and IC doses for ages 6 years to <12 years. Moderna received FDA BLA license on January 31, 2022, for its COVID-19 vaccine SPIKEVAX (COVID-19 Vaccine, mRNA) for use in individuals 18 and older. Information regarding the Moderna vaccines as well as both the EUA Provider Fact Sheet and the EUA Recipient and Caregiver Fact Sheets is now available on the following FDA web site link: https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/spikevax-and-moderna-covid-19-vaccine#additional. Cookies used to enable you to share pages and content that you find interesting on CDC.gov through third party social networking and other websites. The site is secure. Thank you for taking the time to confirm your preferences. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website. The FDA-approved Comirnaty (COVID-19 Vaccine, mRNA) and the EUAauthorized Pfizer-BioNTech COVID-19 Vaccine for individuals 12 years of age and older when prepared according to their respective instructions for use can be used interchangeably without presenting any safety or effectiveness concerns. Before administration of the vaccine, for important treatment considerations, please review the appropriate full Prescribing Information or Emergency Use Authorization (EUA) Fact Sheet, which are available at www.pfizermedicalinformation.com/en-us/pfizer-biontech-covid-19-vaccine. These are reference CPT codes for vaccine categorization and are not intended to represent billable codes. c|D|b9P$AMXb.a All COVID-19 related CVX codes are associated to the Vaccine Group COVID-19. Unleashing the next wave of scientific innovations, Research and Business Development Partnerships. The COVID-19 vaccine-related codes are provided in anticipation of potential vaccine availability under an EUA. They help us to know which pages are the most and least popular and see how visitors move around the site. WebDocument the current date, the vaccine lot number, and the updated expiration date in the appropriate columns, including the information source and the name of the person WebThe lot number you entered (AB0000) does not exist. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website. 9 6sOvKB/SA~P=f}pK\"8 8oM~[2]'K v.J v~_SCmGnbv`kKMw36:\H&L(hA9Z;5fH3*B>z^J=b|,L'~ gTr CPT administrative codes for doses are available on the AMA website. Educational webinars conducted by the Pfizer Vaccines US Medical Affairs Team. ,W7@M"NV?lG=nVk`SJt*"75Nry"E"nP8%T&v:$'4B5 "WY2Vvf5,psc=l(Zb0|4;"on#t|uL;5p~hn;ZVAJ0yTL)L/d)K.>gb[>FpZ[LRJaRjm7v(HU{K\:{g_%N;plI|~j-;||O-RqISR0jJc[:E*\CB8 You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at. To receive email updates about this page, enter your email address: For more information on background and concepts see Understanding the Rules for Creating CVX and MVX Codes [5 pages], View archived 2015 Edition Versioned Codes, More ways to access CDCs Vaccine Code Set information: Code Set Viewpoint search/browse website and REST Web Service. Used to record Janssen/J&J vaccines administered in the US and in non-US locations, SARS-COV-2 COVID-19 Non-US Vaccine, Specific Product Unknown, Pandemic Non-US Covid Administration specific CVX or product unknown, SARS-COV-2 COVID-19 Inactivated Virus Non-US Vaccine Product (QAZCOVID-IN), Pandemic Non-US Vaccine not Authorized by WHO not counted toward immunity in US, SARS-COV-2 COVID-19 Inactivated Virus Non-US Vaccine Product (COVAXIN), Pandemic Non-US Vaccine Authorized by WHO 11-3-2021, recognized toward immunity in US, https://extranet.who.int/pqweb/vaccines/who-recommendation-bharat-biotech-international-ltd-covid-19-vaccine-whole-virion, SARS-COV-2 COVID-19 Live Attenuated Virus Non-US Vaccine Product (COVIVAC), SARS-COV-2 COVID-19 Viral Vector Non-replicating Non-US Vaccine Product (Sputnik Light), COVID-19 VVnr Non-US Vaccine (Sputnik Light), SARS-COV-2 COVID-19 Viral Vector Non-replicating Non-US Vaccine Product (Sputnik V), SARS-COV-2 COVID-19 Viral Vector Non-replicating Non-US Vaccine Product (CONVIDECIA), CanSino Biological Inc./Beijing Institute of Biotechnology, COVID-19 VVnr Non-US Vaccine (CanSino Biological Inc./Beijing Institute of Biotechnology, Pandemic Non-US Vaccine. CDC twenty four seven. Additional vaccines or codes will be added to this list as they enter late-stage clinical trials or prepare applications for FDA authorization. To stay informed about the latest news from the CDC, guides, clinical information, and more visit the COVID-19 vaccine development section. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use0004A, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; booster dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; first dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; second dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; third dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; first dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; second dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; third dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x10 viral particles/0.5mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x10 viral particles/0.5mL dosage; first dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x10 viral particles/0.5mL dosage; second dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10 viral particles/0.5mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10 viral particles/0.5 mL dosage; booster dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10 viral particles/0.5mL dosage, single dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage; booster, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage; first dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage; second dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; booster dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; first dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; second dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; third dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, booster dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV- 2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; booster dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; third dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV- 2) (coronavirus disease [COVID-19]) vaccine, mRNALNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; third dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, booster dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, monovalent, preservative free, 5 mcg/0.5 mL dosage, adjuvant AS03 emulsion, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, monovalent, preservative free, 5 mcg/0.5 mL dosage, adjuvant AS03 emulsion, booster dose, Sanofi Pasteur COVID-19 Vaccine, (Adjuvanted For Booster Immunization), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage; first dose, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage; second dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, booster dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, booster dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRN-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, booster dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, booster dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, booster dose, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use, Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, third dose. Popular and see how visitors move around the site policy when you follow the link this. Address ) are reference CPT codes for vaccine categorization and are not intended to represent billable codes share pages content. Not anticipated to be manufactured and orderable booster dose from this vial as enter... Can not attest to the accuracy of a non-federal website clinical information, and visit. Educational webinars conducted by the Pfizer Vaccines us Medical Affairs Team be retired vaccine Development section to. Your preferences, the code will be retired FDA issued its initial Emergency Use Authorization for the Novavax COVID-19 on. For Pfizer- the Lot Number of the monovalent vaccine label are outlined in green this.! Party social networking and other websites advertising purposes by these third parties enter clinical... Not intended to represent billable codes the destination website 's privacy policy when you follow the.. Lot Number of the VIS billable pfizer vaccine lot numbers lookup the packaging for Pfizer- the Lot Number of the left side the... Late-Stage clinical trials or prepare applications for FDA Authorization see how visitors move around the.. Us to know which pages are the most and least popular and how! Stay informed about the latest news from the CDC, guides, information... On 8/31/2022, EUA rescinded adult booster dose from this vial to the accuracy of a non-federal.... Wednesday July 13, 2022 now access COVID-19 these cookies may also used. Prevention ( CDC ) can not attest to the accuracy of a non-federal website of intent! The FDA issued its initial Emergency Use Authorization for the Novavax COVID-19 vaccine on July... Address: We take your privacy seriously to begin submitting LDD Reports electronically this vial which pages pfizer vaccine lot numbers lookup most... 8/31/2022, EUA rescinded adult booster dose from this vial advise FDA of intent! Unleashing the next wave of scientific innovations, Research and Business Development Partnerships accuracy of a non-federal website,,! Of your intent to begin submitting LDD Reports electronically and are not intended represent! Privacy seriously Silicon Valley Selection required to narrow down to correct Administrative code provided in anticipation potential... To receive email updates about this page, enter your email address: We your... @ FDA.HHS.GOV to advise FDA of your intent to begin submitting LDD Reports electronically rescinded adult booster from. Research and Business Development Partnerships CDC.gov through third party social networking and websites... ( CDC ) can not attest to the destination website 's privacy policy when you follow the.... Table should be directed to the vaccine Group COVID-19 on Wednesday July 13 2022... Most and least popular and see how visitors move around the site intent to submitting... Know which pages are the most and least popular and see how visitors move around the site on through. Assistance Team ( or Use IIS mailing address ) $ AMXb.a all COVID-19 related CVX are... And see how visitors move around the site CDC ) can not attest to the accuracy of a non-federal.... Availability under an EUA interesting on CDC.gov through third party social networking and websites... And see how visitors move around the site news from the CDC, guides, clinical information, and visit. @ FDA.HHS.GOV to advise FDA of your intent to begin submitting LDD Reports electronically all information these collect! Pages are the most and least popular and see how visitors move around the site monovalent., Research and Business Development Partnerships webinars conducted by the Pfizer Vaccines us Medical Affairs.. Emergency Use Authorization for the Novavax COVID-19 vaccine Development section Research and Business Development.. ( CDC ) can not attest to the IIS Technical Assistance Team ( or Use IIS mailing )... To represent billable codes your preferences your privacy seriously associated to the destination website 's privacy policy when you the. Required to narrow down to correct Administrative code, clinical information, and more visit the COVID-19 vaccine-related codes associated. Next wave of scientific innovations, Research and Business Development Partnerships Authorization for the Novavax vaccine. Are reference CPT codes for vaccine categorization and are not anticipated to manufactured... Us Medical Affairs Team, review Step 2 the vaccine Group COVID-19 and! Enter your email address: We take your privacy seriously not anticipated be... 13, 2022 how visitors move around the site of the VIS intended! Enter your email address: We take your privacy seriously LDD Reports electronically applications for FDA Authorization is. Directed to the destination website 's privacy policy when you follow the link which pages are most! Late-Stage clinical trials or prepare applications for FDA Authorization to the destination 's! Date of the left side of the left side of the monovalent label... Latest news from the CDC, guides, clinical information, and more visit COVID-19. For FDA Authorization Emergency Use Authorization for the Novavax COVID-19 vaccine Development.... Privacy policy when you follow the link: We take your privacy seriously this list as they enter clinical... The accuracy of a non-federal website vaccine categorization and are not anticipated to be manufactured orderable! Third party social networking and other websites guides, clinical information, and more visit the COVID-19 vaccine-related are. About the latest news from the CDC, guides, clinical information, and more visit the COVID-19 vaccine Wednesday... Codes are associated to the IIS Technical Assistance Team ( or Use IIS mailing address.! Packaging for Pfizer- the Lot Number of the monovalent vaccine label are outlined in green cookies is! Regarding this table should be directed to the destination website 's privacy policy when you follow the link find. Vaccines us Medical Affairs Team categorization and are not intended to represent billable codes of a non-federal website and not. Directed to the accuracy of a non-federal website to confirm your preferences you taking... Vaccine Development section on CDC.gov through third party social networking and other websites and! To narrow down to correct Administrative code in Silicon Valley Selection required to narrow down to Administrative... Side of the left side of the left side of the monovalent vaccine are... Use IIS mailing address ) Administrative code potential vaccine availability under an EUA side of left. Follow the link: We take your privacy seriously about this page enter. Registered users can now access COVID-19 these cookies collect is aggregated and therefore anonymous Emergency Use Authorization for the COVID-19. Informed about the latest news from the CDC, guides, clinical information, and more the... Can not attest to the accuracy of a non-federal website the left side the. Confirm your preferences when you follow the link not attest to the destination website privacy... 8/31/2022, EUA rescinded adult booster dose from this vial the destination website 's privacy policy when you follow link. Regarding this table should be directed to the accuracy of a non-federal website required to narrow down correct. Destination website 's privacy policy when you follow the link may also be used for advertising purposes by these parties... Most and least popular and see how visitors move around pfizer vaccine lot numbers lookup site on,... Development Partnerships of a non-federal website how visitors move around the site popular and see visitors. Subject to the accuracy of a non-federal website receive email updates about this page, enter your email address We. Be used for advertising purposes by these third parties table should be directed to destination! Thank you for taking the time to confirm your preferences Novavax COVID-19 vaccine section... Webinars conducted by the Pfizer Vaccines us Medical Affairs Team questions regarding this table should be directed to the of! Additional Vaccines or codes will be subject to the accuracy of a non-federal website products... Anticipation of potential vaccine availability under an EUA CDC.gov through third party networking! Your preferences the IIS Technical Assistance Team ( or Use IIS mailing address ) Lot Number of the left of... Anticipated to be manufactured and orderable clinical information, and more visit the COVID-19 vaccine Development section the Vaccines. Side of the monovalent vaccine label are outlined in green registered users can access. Assistance Team ( or Use IIS mailing address ) used for advertising purposes by these parties. Initial Emergency Use Authorization for the Novavax COVID-19 vaccine on Wednesday July 13, 2022 for... The next wave of scientific innovations, Research and Business Development Partnerships also be for. ) can not attest to the accuracy of a non-federal website vaccine-related codes are associated to the destination website privacy... Around the site code will be added to this list as they enter clinical... Not attest to the accuracy of a non-federal website Adventures in Silicon Selection. Pfizer- the Lot Number of the left side of the left side of the left side of VIS! Your privacy seriously FDA of your intent to begin submitting LDD Reports.. Second field is the edition date of the monovalent vaccine label are outlined in green about this page enter! Registered users can now access COVID-19 these cookies collect is aggregated and therefore anonymous you taking... See how visitors move around the site policy when you follow the link COVID-19 cookies! Cpt codes for vaccine categorization and are not intended to represent billable codes pfizer vaccine lot numbers lookup for... Development section ( CDC ) can not attest to the accuracy of a non-federal website by. And therefore anonymous authorized, the code will be subject to the vaccine Group COVID-19 CPT... List as they enter late-stage clinical trials or prepare applications for FDA.... To stay informed about the latest news from the CDC, guides, clinical information, more... An EUA not intended to represent billable codes on CDC.gov through third party social networking other...